Lung Cancer Drug Futures

Date: October 22, 2010
Price:
US$ 2,615.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: L1A038CE0E4EN
Leaflet:

Download PDF Leaflet

Lung Cancer Drug Futures
AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET EVERY INFORMATION NEED

Espicom's Lung Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document. All for one cost-effective annual price of £1,495/US$2,615/€1,865

24/7 web access
Quarterly updated pdf reports
Single cost-effective price
All updates including any new drugs added during your licence period
Related news
Espicom’s research methodology for forecasting and including an explanation of the competitor ratio analysis scoring system.

Although a plethora of platinum-based chemotherapy combinations may be prescribed for the treatment of non small cell lung cancer (NSCLC)....
....the market is currently driven by chemotherapeutic agents such as taxanes and antimetabolites, and the increasing use of targeted therapies. Some of the newer chemotherapy agents such as Eli Lilly’s Gemzar and Alimta have become the standard of care in combination with cisplatin or carboplatin and may be used in addition to or instead of the taxanes Taxotere or Taxol/generic paclitaxel.

The lung cancer market is set for radical change. A number of current first-line therapies will become subject to generic competition in the short term. Although chemotherapy will continue to play a significant if diminishing role, industry attention is firmly on the better-tolerated biologics which are already setting the pace in the market and whose influence will grow over the coming years. In 2007, chemotherapy treatments accounted for 68% of the market but are forecast to account for only 32% by 2014, whereas targeted treatments are forecast to increase from 30% to 60% over the same period.

As researchers begin to understand the processes involved in NSCLC formation, several new targeted therapies have evolved which modulate growth factor pathways. For example, Roche’s small-molecule tyrosine kinase inhibitor Tarceva (erlotinib) and its best selling anti-angiogenic VEGF inhibitor Avastin (bevacizumab) are gaining credence in second- and first-line therapy for advanced disease, respectively.

NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER
This all new web service from Espicom, Lung Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.

WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN...
  • Track the drug’s progress and stay abreast of developments
  • Understand the drug’s novelty and mode of action
  • Evaluate the strength of the company developing/producing the drug
  • Review opportunities and challenges with Espicom’s unique 5-point competitive assessment
  • Know the launch timeframe for new products or indications
  • Be aware of promising mid-stage development candidates
  • Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates
  • Review significant clinical trial results
STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS

For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include…
  • Novelty/rationale for mechanism of action
  • Current status
  • Proof of concept/clinical data
  • Development risks
  • Company expertise
  • Competition within the market-place
  • Sales forecast (for key late-stage and launched products)
  • Competitor ratio analysis score
  • Clinical trial results
OVER 45 CURRENT DRUGS COVERED:
Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.

Approved
  • Bevacizumab
  • Docetaxel
  • Erlotinib
  • Gefitinib
  • Gemcitabine
  • Pemetrexed disodium
  • Paclitaxel
Phase I
  • Everolimus
  • IMO-2055
  • Naptumomab estafenatox
Phase III
  • Aflibercept
  • Belagenpumatucel-L
  • BIBF 1120
  • BIBW 2992
  • Canfosfamide
  • Crizotinib
  • Figitumumab
  • MAGE-A3
  • Motesanib diphosphate
  • Necitumumab
  • PF-02341066
  • PF-299804
  • Sorafenib
  • Stimuvax
  • Sunitinib malate
  • Talactoferrin alpha
  • Vadimezan
Suspended or Discontinued
  • ABT-751
  • Cetuximab
  • Mapatumumab
  • NOV-002
  • Paclitaxel
  • poliglumex
  • Vandetanib
Phase II
  • Arenegyr
  • ARQ 197
  • AT-101
  • Axitinib
  • AZD6244
  • Bavituximab
  • Bortezomib
  • CDP501
  • CDP791
  • Cediranib
  • Cixutumumab
  • Conatumumab
  • Custirsen sodium
  • Dulanermin
  • Enzastaurin
  • Gimatecan
  • Ipilimumab
  • Linifanib
  • lxabepilone
  • MGCD265
  • OGX-011
  • Pazopanib
  • PD-3512676
  • Pertuzumab
  • PF-3512676
  • Ramucirumab
  • Sagopilone
  • STA-9090
  • TG4010
Phase I/II
  • Retaspimycin
  • Tivozanib
  • XL184
CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS

Espicom's Cancer Drug Futures incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon Espicom's established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years’ of archive material.

Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to Espicom's Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.

With Espicom’s Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.

BUILD YOUR OWN DRUG FUTURES LIBRARY WITH 4D RESEARCH!

4D Research is Espicom’s tailored information service. Using 4D Research, customers can build their own Futures library of individual drugs of interest. Indeed, the service can include any of Espicom’s leading information services. Attractive discounts are available to buyers of multiple Futures and our cost-effective distribution license means these key data can be shared with colleagues.

For further information on the products covered, discounts, distribution or a demonstration, please click on the link for Mark Hamson.

CANCER SECTORS COVERED IN THE DRUG FUTURE SERVICE
  • Breast
  • Lung
  • Colorectal
  • Renal Cell Carcinoma
  • Prostate
  • Blood (coming soon)
OVERVIEW

PHASE I

CBP501

EVEROLIMUS


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

IMO255

Mode of Action
Current Status
Proof of Concept/Clinical Data
Company Expertise
Clinical Trial Results:

NAPTUMOMAB ESTAFENATOX

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

PHASE I/II

IXABEPILONE


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

RETASPIMYCIN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

TIVOZANIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

XL184

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

PHASE II

ARENEGYR


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

ARQ197

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results:

AT-101

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

AXITINIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

BAVITUXIMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

BORTEZOMIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast
Clinical Trial Results

CDP791

Clinical Trial Results

CEDIRANIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

CIXUTUMUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

CONATUMUMAB

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

DULANERMIN

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

ENZASTAURIN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

GIMATECAN

Mode of Action
Proof of Concept/Clinical Data

IPILIMUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

LINIFANIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

MGCD265

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

OGX-011

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

PAZOPANIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Competitor Ratio Analysis
Forecast

PERTUZUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

PF-3512676

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

RAMUCIRUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

SAGOPILONE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

STA-9090

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

PHASE III

AFLIBERCEPT


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

BIBF 1120

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

BELAGENPUMATUCEL-L

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

BIBW 2992

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

CANFOSFAMIDE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

CRIZOTINIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

FIGITUMUMAB

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

MAGE-A3

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

MOTESANIB DIPHOSPHATE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

NECITUMUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

PF-299804

Mode of Action
Current Status
Proof of Concept/Clinical Data

SORAFENIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Competitor Ratio Analysis
Forecast

LAUNCHED PRODUCTS

BEVACIZUMAB


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

DOCETAXEL

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

ERLOTINIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Generic Competition
Clinical Trial Results

GEFITINIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

GEMCITABINE

Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast
Metastatic Breast Cancer
Pancreatic Cancer

PACLITAXEL

PEMETREXED DISODIUM


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast
Advanced and Metastatic Hepatoma
Metastatic Breast Cancer

SUSPENDED

MAPATUMUMAB


Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

WITHDRAWN/DISCONTINUED

ABT-751


Mode of Action
Current Status

NOV-002

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

METHODOLOGY
Skip to top


Breast Cancer Drug Futures US$ 2,615.00 Oct, 2010
Colorectal Cancer Drug Futures US$ 2,615.00 Oct, 2010

Ask Your Question

Lung Cancer Drug Futures
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: